Deals In Depth: November 2013
Executive Summary
Egalet secured Shionogi as its first major partner in a deal focused on abuse-deterring forms of hydrocodone; to complement its specialty pharmacy portfolio, CVS acquired the infusion therapy business Coram for $2.1 billion. A $729 million debt offering by Incyte made up nearly one-third of the $2.5 billion in biopharma financing; and sources of public fundraising have been increasing over the past few months in the device industry, which raised $532 million.
You may also be interested in...
Asia Deal Watch: Perceptive Launches LianBio With “China-Centric” Strategy
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
FDA Revokes Second COVID-19 Diagnostic EUA Over Performance Concerns
Autobio’s test reportedly only correctly identified half the positive COVID-19 samples in an NIH evaluation.
US GAO Review Of FDA’s OTC Drug Oversight Signals Waiting For Monograph Reform Benefits
Benefits of OTC monograph reform legislation passed in March likely will take at least several years, according to GAO report to Congress. It notes the FDA still is analyzing the legislation and it may need two years to add and train staff.
Need a specific report? 1000+ reports available
Buy Reports